LYVE1 and neoplasm: To determine the effect of CAFs on the lymphatic endothelial barrier in the TME of CSCC, quadruple immunofluorescent staining was performed on the primary tumor samples obtained from 77 CSCC patients (consisting of 57 CSCC patients without LNM [CSCCnon‐LNM] and 20 with LNM [CSCCLNM]), using α‐SMA (CAF marker), LYVE‐1 (lymphatic marker), VE‐cadherin, and DAPI (nuclear marker).